Havrix Monodose Vaccine

Havrix Monodose Vaccine is an injectable solution that contains inactivated hepatitis A virus as the active ingredient and algeldrate as an adjuvant. The product is supplied in a single‑dose vial, strength not specified, and is administered intramuscularly. It is a prescription vaccine marketed in the European Union for preventing hepatitis A infection and is classified under ATC code J07BC01 for individuals at risk of exposure to the virus.

Havrix Monodose Vaccine is indicated for the active immunization against hepatitis A virus.

- Primary prevention of hepatitis A infection in adults and children aged one year and older. - Post‑exposure prophylaxis for persons who have had recent contact with a confirmed hepatitis A case. - Immunization of travelers heading to regions where hepatitis A is endemic or of intermediate prevalence. - Protection of individuals with chronic liver disease, clotting factor deficiencies, or other conditions that increase risk of severe hepatitis A. - Use in public health outbreak control measures to rapidly increase population immunity.

The safety profile of Havrix Monodose Vaccine includes a range of reactions that are typically mild and transient, as well as rare events that may require medical attention.

Common: - Pain, redness, or swelling at the injection site, usually mild and short‑lasting. - Low‑grade fever (up to 38.5 °C) within 24 hours, lasting 1–2 days. - Headache or fatigue that is transient and improves without treatment. - Mild muscle aches or joint discomfort occurring shortly after injection. - Nausea or mild stomach upset that resolves on its own.

Serious: - Severe allergic reaction (anaphylaxis) with hives, breathing difficulty, or shock; needs emergency care. - Guillain‑Barré syndrome, a rare autoimmune neuropathy reported in isolated cases after vaccination. - High fever with chills or persistent neurological symptoms that require prompt medical evaluation.

Precautions for Havrix Monodose Vaccine focus on patient history, immune status, and potential contraindications.

- Do not administer to individuals with known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in persons with acute moderate or severe illness until recovery. - Use with caution in pregnant or breastfeeding women; discuss risk‑benefit with healthcare provider. - Evaluate immunocompromised patients, as response may be reduced; vaccination may still be recommended. - Post‑vaccination observation for at least 15 minutes is advised to monitor for immediate reactions.

Havrix Monodose Vaccine may interact with other agents that affect the immune system or increase the risk of hypersensitivity.

Avoid: - Live attenuated vaccines administered within 4 weeks before or after Havrix, as immune response may be altered. - Immunoglobulin or blood products given within 2 weeks of vaccination, which can reduce vaccine efficacy.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody response; timing should be coordinated. - Antipyretics (acetaminophen, ibuprofen) taken prophylactically may mask mild fever; use only if needed. - Chronic liver disease or clotting disorders; monitor for bleeding at injection site.